PULM

$2.11

Market ClosedAs of Mar 17, 8:00 PM UTC

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

TipRanks
Mar 3, 2026

Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction

Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies, in an all-stock transaction valued at approximately $300M. Following the closure of the acquisition, the new combined entity will be a fully integrated biopharmaceutical company with U.S.- and China-based capabilities spanning from discovery to manufacturing

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.